Cytomegalovirus (CMV) is associated with detrimental outcomes after lung transplantation (LTX); primary prophylaxis (PPX) with valganciclovir (VGC) is guideline‐recommended. VGC is associated with myelosuppression, spurring interest in letermovir (LTV). Click to show full abstract
Cytomegalovirus (CMV) is associated with detrimental outcomes after lung transplantation (LTX); primary prophylaxis (PPX) with valganciclovir (VGC) is guideline‐recommended. VGC is associated with myelosuppression, spurring interest in letermovir (LTV).
Keywords:
letermovir cytomegalovirus;
impact letermovir;
myelosuppression;
cytomegalovirus;
primary prophylaxis
Journal Title: Clinical Transplantation
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Transplantation
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!